A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.
Research Roundup: Two Types of Parkinson’s Disease and More
Adults, Aging, Biomarkers, Boston University, Brain, Cell Stem Cell, Children, Denmark, Duke University, Epigenetic, Eye Health, Human beings, Inflammatory Proteins, Lung Inflammation, Lupus, Nerve Cells, Neurodegeneration, Parkinson’s disease, Primates, R&D, Research, Science Translational Medicine, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), UniversitiesResearchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
Biohaven Pharmaceutical Holding Co. Ltd. said the U.S. health regulator failed to approve the company’s treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
Jacobus Pharmaceutical Co. Inc. won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.
Sangamo Therapeutics Inc. and Pfizer Inc. are partnering to develop a gene therapy to treat a disease that affects nerve cells in the brain and the spinal cord.
A common antibiotic called doxycycline can disrupt the formation of negative thoughts and fears in the brain and may prove useful in treating or preventing post traumatic stress disorder (PTSD), according to research by British and Swiss scientists.
Brain scans of 23 Brazilian infants with the birth defect microcephaly showed widespread and severe abnormalities suggesting that Zika may invade fetal nerve cells and disrupt brain development. The findings, published on Wednesday in a letter to the New England Journal of Medicine, are based on a large trove of computed tomography, or CT […]
Sanofi Walks Away from a $613 Million Multiple Sclerosis Pact with Glenmark Pharma
Autoimmune Disease, Autoimmune Diseases, Brain Infections, Clinical Trials, Forecasts, Health, Immune Cells, Monoclonal Antibodies, Monoclonal Antibodies, Multiple Sclerosis, Multiple Sclerosis, Nerve Cells, Pain & Inflammation, R&D, Sales, TherapeuticsPARIS – After experimental multiple sclerosis drug vatelizumab failed to meet its primary endpoints in a mid-stage trial, Sanofi AG (SNY) said it has dropped plans to develop the drug with India-based Glenmark Pharmaceuticals. During a second-quarter results analysis with media members, Glenmark revealed that Sanofi was terminating the development agreement for vatelizumab, also […]